Release time：Sep 17, 2021
On September 16, 2021, Hang Yingwei, Deputy Secretary-General of Shanghai Municipal Government, Deputy Party Secretary of the District Committee and Director of Pudong New Area, and Standing Deputy Director of the Shanghai Science and Technology Innovation Promotion Office, made an on-site investigation & research and instruction to Mabwell. Accompanied by Dr. Liu Datao, co-founder and CEO of the company, Hang and his team visited Mabwell Innovation and R&D Center for biological antibody drugs, listened to the company’s report, and learned about the capability of source innovation strength and independent innovation strength on site.
Dr. Liu Datao (left) introduced Mabwell to Hang Yingwei, District Director (Middle) and Peng Song, Member of the District Standing Committee (Right)
During the investigation & research, Dr. Liu Datao reported on the scientific and technological innovation construction and development of Mabwell to Hang Yingwei, District Director. In his report, Dr. Liu focused on the company’s strategy of building the capability of sustainable innovation strength as the core, creating an innovative system which is underpinned by the discovery of antibody drug molecules and covers every aspects in the entire cycle of drug R&D including druggability study, preclinical study, clinical study and production transformation and ultimately completing the layout of the entire industrial chain and achieving the global commercialization goals. At present, Mabwell has dozens of drug candidates in different R&D stages based on a world-class and state-of-the-art R&D engine. Of these, 1 BLA has been filed, 8 products are in different stages of clinical study and 2 products have been approved for clinical trials initiation. Dr. Liu also introduced the leading advantages of key products in clinical stage, as well as innovative strategies and prospects of achievements in recent years.
Dr. Liu Datao introduced Mabwell Biological Innovation and R&D Center to Hang Yingwei, District Director
After listening to the report of Dr. Liu Datao, Hang Yingwei, District Director fully acknowledged Mabwell's capability of innovation strength, and also gave concern and expectation to the future development of Mabwell. He pointed out that the bioengineering and pharmaceutical industry is one of the leading and dominant industries in Zhangjiang Science City. Zhangjiang should continue to support the promotion for R&D innovation of more biomedical enterprises, constantly improve the industrial competence level and core competitive strength of Zhangjiang innovative drug industry, and develop more innovative drugs to benefit the people.
Strive to strengthen the innovation engine and create a new highland of independent innovation! As an innovation-oriented biopharmaceutical enterprise, Mabwell is committed to innovation in the field of biopharmaceutical science and technology, focusing on breakthroughs in key core technical areas. Mabwell has undertaken numbers of national, provincial and municipal science and technology innovation projects, which fully reflects the company’s capability of source innovation strength and industrial transformation strength.
Peng Song, Executive Deputy Director of the Shanghai Science and Technology Innovation Promotion Office, Member of the District Standing Committee of Pudong New Area, participated in the investigation & research, and the leaders of the Pudong New Area Government Office, Zhangjiang Administration Bureau and relevant government organizations accompanied the investigation & research.
